[go: up one dir, main page]

MXPA05012880A - Inhibidores de complemento. - Google Patents

Inhibidores de complemento.

Info

Publication number
MXPA05012880A
MXPA05012880A MXPA05012880A MXPA05012880A MXPA05012880A MX PA05012880 A MXPA05012880 A MX PA05012880A MX PA05012880 A MXPA05012880 A MX PA05012880A MX PA05012880 A MXPA05012880 A MX PA05012880A MX PA05012880 A MXPA05012880 A MX PA05012880A
Authority
MX
Mexico
Prior art keywords
complement inhibitors
ticks
complement
relates
inhibitors
Prior art date
Application number
MXPA05012880A
Other languages
English (en)
Inventor
Miles Andrew Nunn
Original Assignee
Evolutec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312619A external-priority patent/GB0312619D0/en
Priority claimed from GB0327386A external-priority patent/GB0327386D0/en
Application filed by Evolutec Ltd filed Critical Evolutec Ltd
Publication of MXPA05012880A publication Critical patent/MXPA05012880A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
    • G01N2333/43556—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects from ticks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/42—Poisoning, e.g. from bites or stings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)

Abstract

La invencion se relaciona con inhibidores de complemento que inhiben las rutas de complemento clasica y alternativa. En particular, la invencion se relaciona con inhibidores de complemento derivados de las glandulas salivales de artropodos hematofagos, que inhiben las rutas de complemento clasica y alternativa. La invencion tambien se refiere al uso de tales inhibidores de complemento en el tratamiento y prevencion de enfermedades.
MXPA05012880A 2003-06-02 2004-06-02 Inhibidores de complemento. MXPA05012880A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0312619A GB0312619D0 (en) 2003-06-02 2003-06-02 Complement inhibitors
GB0327386A GB0327386D0 (en) 2003-11-25 2003-11-25 Complement inhibitors
PCT/GB2004/002341 WO2004106369A2 (en) 2003-06-02 2004-06-02 Complement inhibitors from ticks

Publications (1)

Publication Number Publication Date
MXPA05012880A true MXPA05012880A (es) 2006-02-22

Family

ID=33492257

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012880A MXPA05012880A (es) 2003-06-02 2004-06-02 Inhibidores de complemento.

Country Status (12)

Country Link
US (5) US7884188B2 (es)
EP (1) EP1629098B1 (es)
JP (1) JP4772667B2 (es)
AT (1) ATE427356T1 (es)
AU (1) AU2004242759B2 (es)
BR (1) BRPI0410876B8 (es)
CA (1) CA2526083C (es)
DE (1) DE602004020334D1 (es)
ES (1) ES2324993T3 (es)
MX (1) MXPA05012880A (es)
NZ (1) NZ544163A (es)
WO (1) WO2004106369A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106369A2 (en) * 2003-06-02 2004-12-09 Evolutec Limited Complement inhibitors from ticks
JP5137053B2 (ja) 2004-02-10 2013-02-06 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬
NZ608860A (en) 2005-02-14 2014-10-31 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
JP5707024B2 (ja) 2005-05-26 2015-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
RU2440824C2 (ru) * 2005-12-12 2012-01-27 Ац Иммуне Са Терапевтическая вакцина
WO2008029169A2 (en) * 2006-09-08 2008-03-13 Varleigh Limited Method of treating respiratory disorders
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
PL2148691T3 (pl) * 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
BRPI0808227A2 (pt) 2007-03-14 2014-07-08 Taligen Therapeutics Inc Anticorpo humanizado anti-fator b
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009151634A1 (en) * 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
CN101928709B (zh) * 2009-06-24 2012-05-23 中国农业科学院上海兽医研究所 一种亚洲璃眼蜱的组胺结合蛋白HaHBP的基因序列和重组表达与应用
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
NZ601018A (en) * 2010-01-08 2013-09-27 Varleigh Immuno Pharmaceuticals Ltd Ev576 for use in the treatment of viral infections of the respiratory tract
US20130058931A1 (en) 2010-03-11 2013-03-07 University Of Louisville Research Foundation, Inc. Methods of predicting and decreasing the risk of pregnancy loss
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
CN103826659A (zh) * 2011-06-20 2014-05-28 圣路易斯大学 用于治疗的靶向神经肌肉接头
BR112013033272A2 (pt) 2011-06-22 2020-11-10 Apellis Pharmaceuticals, Inc. composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos
ES2715638T3 (es) 2012-02-20 2019-06-05 Swedish Orphan Biovitrum Ab Publ Polipéptidos que se unen al complemento humano C5
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2017210537A1 (en) 2016-06-02 2017-12-07 The Cleveland Clinic Foundation Complement inhibition for improving cell viability
KR102667023B1 (ko) 2016-06-14 2024-05-21 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
IL269895B2 (en) 2017-04-21 2024-06-01 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
EP3724226A1 (en) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
US20220047673A1 (en) 2018-09-10 2022-02-17 Volution Immuno Pharmaceuticals Sa Coversin for Use in the Treatment of Rheumatic Diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
US20220370556A1 (en) 2019-09-27 2022-11-24 Volution Immuno Pharmaceuticals Sa Method of Treatment
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017099A1 (en) * 1992-02-27 1993-09-02 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation
US7884066B2 (en) * 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2004106369A2 (en) * 2003-06-02 2004-12-09 Evolutec Limited Complement inhibitors from ticks

Also Published As

Publication number Publication date
JP2007536894A (ja) 2007-12-20
WO2004106369A3 (en) 2005-02-17
US20220363726A1 (en) 2022-11-17
US20070141573A1 (en) 2007-06-21
BRPI0410876B1 (pt) 2020-11-03
DE602004020334D1 (de) 2009-05-14
CA2526083C (en) 2017-01-17
AU2004242759B2 (en) 2009-11-26
US20180127472A1 (en) 2018-05-10
AU2004242759A1 (en) 2004-12-09
ATE427356T1 (de) 2009-04-15
WO2004106369A2 (en) 2004-12-09
JP4772667B2 (ja) 2011-09-14
US9834585B2 (en) 2017-12-05
EP1629098B1 (en) 2009-04-01
BRPI0410876B8 (pt) 2023-01-24
HK1085511A1 (en) 2006-08-25
CA2526083A1 (en) 2004-12-09
US7884188B2 (en) 2011-02-08
US20110263482A1 (en) 2011-10-27
BRPI0410876A (pt) 2006-07-04
EP1629098A2 (en) 2006-03-01
ES2324993T3 (es) 2009-08-21
US8993264B2 (en) 2015-03-31
US20160096870A1 (en) 2016-04-07
NZ544163A (en) 2009-06-26

Similar Documents

Publication Publication Date Title
MXPA05012880A (es) Inhibidores de complemento.
TNSN05044A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
GB0223040D0 (en) Therapeutic compounds
MXPA05012812A (es) Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp).
IS2923B (is) Aðferðir til að meðhöndla eða fyrirbyggja með 2,4-pýrimidíndíamínefnasamböndum sjálfsónæmissjúkdóma
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
MXPA05011886A (es) Metodos y composiciones para la prevencion y tratamiento de septicemia.
NO20034056D0 (no) Proliferative sykdommer
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
NO20071078L (no) Antivirale forbindelser
NO20070866L (no) Antivirale forbindelser.
WO2006024018A3 (en) Compositions for treating nociceptive pain
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2004006858A3 (en) Compounds, compositions, and methods employing same
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
UA86345C2 (ru) Применение остеопротегерина для лечения и/или предотвращения фиброза
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
DE60329326D1 (de) Tace inhibitoren
WO2004060878A3 (en) Inhibitors of phosphatases
WO2003072053A3 (en) Compounds for treatment of copper overload
MXPA04003910A (es) Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
IN2015DN03331A (es)
UA85187C2 (en) 2-aminobenzoyl derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal